The US Food and Drug Administration (FDA) has approved Antares Pharma's (Antares) OTREXUP, a single-dose, disposable auto-injector for the subcutaneous (SC) once-weekly administration of methotrexate (MTX). OTREXUP is reportedly the first ...
CureDuchenne has launched a new drug discovery and development initiative to identify and develop a pipeline of therapies to treat Duchenne muscular dystrophy. The initiative, dubbed CureDuchenne Ventures, is based on the company's ...
Swedish biotechnology firm Karo Bio (KARO) has achieved its first milestone in a research agreement with Pfizer for the development of drugs for treatment of autoimmune diseases. The achievement of milestone in the RORgamma project ...
Can-Fite BioPharma, the parent company of OphthaliX, received a patent entitled ‘Adenosine A3 receptor agonists for the treatment of dry eye disorders including Sjogren’s syndrome’ from the European Patent Office. The ...
Tags: Can-Fite BioPharma
Japanese firms Ono Pharma and Bristol-Myers KK (BMKK) have rolled out the rheumatoid arthritis drug, Orencia Subcutaneous Injection 125mg Syringe 1ml, in Japan. Orencia SC, whose generic name is abatacept, restrains the discharge of ...
An infrared sauna uses infrared heaters to emit infrared light experienced as radiant heat which is absorbed by the surface of the skin. Traditional saunas heat the body primary by conduction and convection from the heated air and by ...
The European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) has confirmed its opinion for European marketing authorization of Pfizer's Xeljanz (tofacitinib citrate). Xeljanz is a novel, oral Janus kinase ...
AbbVie's Humira (adalimumab), a rheumatoid arthritis drug, has been rejected by the US FDA advisors for use in the treatment of a spinal inflammatory disease, non-radiographic axial spondyloarthritis. The FDA's Arthritis Advisory ...
The US FDA has approved Janssen Biotech's Simponi ARIA (golimumab) for infusion to treat moderately to severely active rheumatoid arthritis (RA). Simponi ARIA is the only fully-human anti-tumor necrosis factor (TNF)-alpha infusible ...
Pfizer's rheumatoid arthritis treatment, tofacitinib, has obtained approval in several additional countries globally, including Switzerland, Argentina, Kuwait, UAE and Russia for patients with inadequate response to current therapies. The ...
The USFDA has accepted Pfizer's supplemental new drug application (sNDA) to expand labeling of rheumatoid arthritis medication Xeljanz (tofacitinib citrate) to include inhibition of structural damage progression. The data from ORAL Start ...
Tags: FDA, Pfizer sNDA, Xeljanz Labeling
Bristol-Myers Squibb and Simcere Pharmaceutical Group have extended their collaboration to develop and commercialize the subcutaneous (SC) formulation of Bristol-Myers Squibb's biologic medicine, Orencia (abatacept), in China. Orencia was ...
Tags: Bristol-Myers Squibb, Medicine
The European Medicines Agency has cleared Roche's RoACTEMRA for the treatment of a rare form of arthritis, polyarticular juvenile idiopathic arthritis (PJIA), in children aged two years and above. Approved for use alone or in combination ...
Tags: Arthritis Drug, Medicine
Sanofi and Regeneron Pharmaceuticals have announced the commencement of patient enrollment in two Phase 3 rheumatoid arthritis (RA) trials, the COMPARE and ASCERTAIN trials, with Sarilumab. The first fully human monoclonal antibody ...
Galapagos and AbbVie have extended their GLPG0634 clinical development collaboration to include Crohn's disease. As per the extension agreement, Galapagos will fund and complete a Phase 2 program in Crohn's disease, which is designed to ...
Tags: AbbVie, Galapagos, Crohn's Disease